Robotic-assisted thoracoscopic segmentectomy results in lower intraoperative blood loss compared to video-assisted thoracoscopic segmentectomyRobotic surgery shows less blood loss for early lung cancer

This meta-analysis evaluated the comparative outcomes of robotic-assisted thoracoscopic segmentectomy (RATS) and video-assisted thoracoscopic segmentectomy (VATS) in a large cohort of 14,007 patients diagnosed with early-stage non-small cell lung cancer (NSCLC). The study utilized propensity-matched data to minimize selection bias between the two surgical techniques, providing a comprehensive overview of surgical efficacy and safety in this patient population.

The primary focus of the analysis was to determine if the use of robotic platforms versus traditional video-assisted systems influenced perioperative outcomes or oncologic results. The intervention group underwent RATS, while the comparator group underwent VATS. The study specifically looked at several key metrics including intraoperative blood loss, overall survival, operative time, cost, nodal assessment, chest drainage duration, hospital length of stay, conversion to thoracotomy, 30-day readmission, persistent air leak, atrial arrhythmia, and 90-day mortality.

Regarding the primary finding of interest, RATS was associated with significantly lower intraoperative blood loss compared to VATS. The mean difference (MD) was -8.82 (95% CI -16.37 to -1.28, p = 0.02). This indicates a statistically significant reduction in blood loss for patients undergoing the robotic approach. Other critical surgical metrics, including operative time, cost, nodal assessment, chest drainage duration, hospital length of stay, conversion to thoracotomy, 30-day readmission, persistent air leak, atrial arrhythmia, and 90-day mortality, were found to be comparable between the RATS and VATS groups. No significant differences were reported for these secondary outcomes.

In terms of long-term outcomes, the analysis found that overall survival was similar between the two groups. The hazard ratio (HR) was 0.98 (95% CI 0.90 to 1.08, p = 0.72). The median survival for both the RATS and VATS groups was 4.6 years. These data suggest that the choice of surgical platform does not impact the long-term survival of patients with early-stage NSCLC.

Safety and tolerability data were not specifically detailed in terms of adverse event rates or serious adverse events in the provided evidence. However, the comparable rates of conversion to thoracotomy and 90-day mortality suggest that both techniques are safe for the management of early-stage NSCLC. The lack of significant difference in complications such as persistent air leaks or atrial arrhythmias further supports the clinical equivalence of the two methods in terms of immediate postoperative safety.

These results align with the general understanding that both RATS and VATS are viable and effective surgical techniques for lung cancer. While RATS shows a specific advantage in reducing intraoperative blood loss, the lack of difference in survival and other major complications suggests that the choice between RATS and VATS may depend on institutional preference, surgeon expertise, and logistical considerations rather than a significant difference in oncologic outcomes. Methodological limitations include the fact that this is a meta-analysis of propensity-matched studies rather than a randomized controlled trial, which may introduce some inherent bias. Additionally, several specific data points regarding safety were not reported in the summary. Clinically, these results suggest that both RATS and VATS provide comparable perioperative safety and oncologic adequacy for patients with early-stage NSCLC. Future research may need to address specific factors influencing the reduction in blood loss in the RATS group to better understand the technical advantages of the robotic platform.